Literature DB >> 17350673

True difference or something else? Problems in cost of osteoarthritis studies.

Feng Xie1, Julian Thumboo, Shu-Chuen Li.   

Abstract

OBJECTIVES: To identify the commonalities and discrepancies among the published cost of osteoarthritis (OA) studies and to further propose some potential improvements for this type of research.
METHODS: A systematic literature review was performed on MEDLINE (1966 to April 2006) by using 2 overlapping search strategies to identify cost of illness studies in OA based on the predefined eligible criteria. Direct and indirect costs per patient per annum were separately summarized across studies and countries. The sample size-weighted mean was calculated when there were 2 or more studies from the same country. Discount rates of 3% and appropriate exchange rates were used in conversion of the costs reported in different years and different currencies to 2005 US dollars.
RESULTS: Ten articles fulfilling the eligible criteria were included in the literature synthesis. Of these, 4 were from the USA, 2 each from Canada and France, and 1 each from Italy and Hong Kong. After adjusted to 2005 US dollars, annual direct costs per patient (in descending order) were $9147 in Hong Kong, $4792 in USA, $2878 in Canada, $1271 in Italy, and $345 in France. In contrast, indirect costs were only reported by 5 studies in 4 countries. The highest indirect costs were $9847 per patient per annum in Canada and the lowest were $864 in Hong Kong.
CONCLUSIONS: The observed substantial variations in costs of OA across studies and countries may not reflect the true differences among them. The comparability across these identified studies is quite limited, which highlights the importance of standardization in cost of OA studies.

Entities:  

Mesh:

Year:  2007        PMID: 17350673     DOI: 10.1016/j.semarthrit.2007.01.001

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  7 in total

1.  Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty.

Authors:  Elena Losina; A David Paltiel; Alexander M Weinstein; Edward Yelin; David J Hunter; Stephanie P Chen; Kristina Klara; Lisa G Suter; Daniel H Solomon; Sara A Burbine; Rochelle P Walensky; Jeffrey N Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-02       Impact factor: 4.794

Review 2.  Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.

Authors:  Fei-Li Zhao; Feng Xie; Hao Hu; Shu-Chuen Li
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

3.  Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations.

Authors:  Tobias D Henning; Rakhee Gawande; Aman Khurana; Sidhartha Tavri; Lydia Mandrussow; Daniel Golovko; Andrew Horvai; Barbara Sennino; Donald McDonald; Reinhard Meier; Michael Wendland; Nikita Derugin; Thomas M Link; Heike E Daldrup-Link
Journal:  Mol Imaging       Date:  2012-06       Impact factor: 4.488

Review 4.  Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.

Authors:  Feng Xie; Bruno Kovic; Xuejing Jin; Xiaoning He; Mengxiao Wang; Camila Silvestre
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  Health care costs in US patients with and without a diagnosis of osteoarthritis.

Authors:  T Kim Le; Leslie B Montejano; Zhun Cao; Yang Zhao; Dennis Ang
Journal:  J Pain Res       Date:  2012-02-01       Impact factor: 3.133

6.  The Global Economic Cost of Osteoarthritis: How the UK Compares.

Authors:  A Chen; C Gupte; K Akhtar; P Smith; J Cobb
Journal:  Arthritis       Date:  2012-10-02

7.  How much do rheumatologists and orthopaedists doctors' modalities impact the cost of arthritis in Cyprus?

Authors:  Despena Andrioti; Kypros Kyprianou; George Charalambous
Journal:  BMC Musculoskelet Disord       Date:  2015-08-14       Impact factor: 2.362

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.